• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Statistical analysis br Statistical analyses were


    5. Statistical analysis
    Statistical analyses were performed using GraphPad Prism 5 soft-ware. Results are presented as mean values ± standard deviations (S.D.) and/or standard errors of the means (S.E.M.) for quantitative data. Statistical significance was determined using ANOVA with the Tukey's multiple comparison test, unpaired or paired t-tests. P-va-lues < .05 were considered statistically significant.
    Competing Interest
    We also declare that there aren't competing financial interests in relation to the work described.
    Authors' contributions
    O.F., M.Mo and D.D.P. designed the study; acquired, analyzed and interpreted the data; and drafted the manuscript. C.B., G.C., P.G., and V.B. acquired and analyzed the data. M.Mi., U.P., P.P., M.P., and G.S. designed the study, interpreted the data, and critically revised the manuscript. All authors approved the final version of the manuscript.
    Declarations of Competing Interest
    [26] C. Brignole, F. Pastorino, D. Marimpietri, G. Pagnan, A. Pistorio, et al., Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonu-cleotides containing CpG motifs, J. Natl. Cancer Inst. 96 (2004) 1171–1180.
    [27] P. Perri, D. DiPaolo, L. Priddy, A. Fiore, C. Brignole, et al., MicroRNA replacement and RNAi-mediated silencing of ALK as combined targeted therapies for neuro-blastoma, Cancer Res Suppl 74: Meeting Abstract 1453, 2014.
    [28] M. Moro, G. Bertolini, R. Caserini, C. Borzi, M. Boeri, et al., Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness, Sci. Rep. 7 (2017) 6689. [29] F. Piaggio, V. Kondylis, F. Pastorino, D. Di Paolo, P. Perri, et al., A novel liposomal Clodronate depletes tumor-associated Luteolin in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects, J. Control. Release 223 (2016) 165–177.
    [30] M. Loi, P. Becherini, L. Emionite, A. Giacomini, I. Cossu, et al., sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tu-mour resistance in combination with Bortezomib, J. Control. Release 192 (2014)
    [33] M. Higashiyama, O. Doi, K. Kodama, H. Yokouchi, T. Kasugai, et al., MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation, Br. J. Cancer 75 (1997) 1302–1308.
    [34] G. Pagnan, D.D. Stuart, F. Pastorino, L. Raffaghello, P.G. Montaldo, et al., Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via dis-ialoganglioside GD(2)-targeted immunoliposomes: antitumor effects, J. Natl. Cancer Inst. 92 (2000) 253–261.
    [35] C. Brignole, G. Pagnan, D. Marimpietri, E. Cosimo, T.M. Allen, et al., Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment, Cancer Lett. 197 (2003) 231–235.
    [49] F. Pastorino, C. Brignole, D. Di Paolo, P. Perri, F. Curnis, et al., Overcoming bio-logical barriers in Neuroblastoma therapy: the vascular targeting approach with liposomal drug Nanocarriers, Small 15 (2019) e1804591.
    [54] O. Fortunato, C. Borzi, M. Milione, G. Centonze, D. Conte, et al., Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk, Int J Cancer, 2018.
    [56] M. Moro, G. Bertolini, M. Tortoreto, U. Pastorino, G. Sozzi, et al., Patient-derived Xenografts of non-small cell lung Cancer: resurgence of an old model for in-vestigation of modern concepts of tailored therapy and cancer stem cells, J. Biomed. Biotechnol. 2012 (2012) 568567.